Mechanisms of oral carcinogenesis induced by dibenzo[a,l]pyrene: An environmental pollutant and a tobacco smoke constituent

We previously reported that dibenzo[a,l]pyrene (DB[a,l]P), the most potent known environmental carcinogen among polycyclic aromatic hydrocarbons (PAH) congeners, is carcinogenic in the oral tissues of mice. We have now developed a new mouse model which employs the oral application of the fjord region diol epoxide, (±)‐anti−11,12‐dihydroxy‐13,14‐epoxy‐11,12,13,14‐tetrahydrodibenzo[a,l]pyrene (DB[a,l]PDE), a metabolite of the tobacco smoke constituent DB[a,l]P, and we show its specific induction of oral squamous cell carcinoma (OSCC) in both tongue and other oral tissues. Groups of B6C3F1 mice (20/group) received 6 or 3 nmol of (±)‐anti‐DB[a,l]PDE administered into the oral cavity; 3 times per week for 38 weeks. Additional groups received the vehicle alone or were left untreated. Mice were sacrificed 42 weeks after the first carcinogen administration. The high dose induced 74 and 100% OSCC in the tongue and other oral tissues, respectively; the corresponding values at the lower dose were 45 and 89%. Using immunohistochemistry, we showed that DB[a,l]PDE resulted in overexpression of p53 and COX‐2 proteins in malignant tissues when compared to normal oral tissues and tongues. Consistent with the carcinogenicity, we demonstrated powerful mutagenicity in cII gene in B6C3F1 (Big Blue) mouse tongue. The mutational profile in lacI reporter gene is similar to those detected in human head and neck cancer, and p53 mutations were observed in mouse oral tumor tissues. Taken together, we conclude that the formation of diol epoxides plays a major role among the mechanisms by which DB[a,l]P exerts its oral mutagenicity and tumorigenicity.

[1]  K. Rudolph,et al.  DNA damage checkpoints in stem cells, ageing and cancer , 2012, Nature Reviews Molecular Cell Biology.

[2]  K. Ahn,et al.  Mutagenesis and carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: a potential new model for oral cancer , 2012, International journal of cancer.

[3]  S. Amin,et al.  Induction of ovarian cancer and DNA adducts by Dibenzo[a,l]pyrene in the mouse. , 2012, Chemical research in toxicology.

[4]  S. Amin,et al.  Identification and quantification of DNA adducts in the oral tissues of mice treated with the environmental carcinogen dibenzo[a,l]pyrene by HPLC-MS/MS. , 2011, Chemical research in toxicology.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  R. Mendes,et al.  An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. , 2009, Oral oncology.

[7]  A. Molinolo,et al.  Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. , 2009, Cancer research.

[8]  V. Patel,et al.  Chemical Carcinogenesis Models for Evaluating Molecular-Targeted Prevention and Treatment of Oral Cancer , 2009, Cancer Prevention Research.

[9]  Ru-Fang Yeh,et al.  Epigenetic profiling reveals etiologically distinct patterns of DNA methylation in head and neck squamous cell carcinoma. , 2009, Carcinogenesis.

[10]  K. Wong.  Oral-Specific Chemical Carcinogenesis in Mice: An Exciting Model for Cancer Prevention and Therapy , 2009, Cancer Prevention Research.

[11]  M. George,et al.  Mutations induced by benzo[a]pyrene and dibenzo[a,l]pyrene in lacI transgenic B6C3F1 mouse lung result from stable DNA adducts. , 2008, Mutagenesis.

[12]  S. Shetty,et al.  Regulation of Plasminogen Activator Inhibitor-1 Expression by Tumor Suppressor Protein p53* , 2008, Journal of Biological Chemistry.

[13]  P. Laurent-Puig,et al.  Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma , 2008, BMC Medical Genomics.

[14]  J. Eyfjörd,et al.  MYC amplification and TERT expression in breast tumor progression. , 2007, Cancer genetics and cytogenetics.

[15]  Clifton D Fuller,et al.  Conditional survival in head and neck squamous cell carcinoma , 2007, Cancer.

[16]  K. Pavelka,et al.  Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[17]  C. Leonetti,et al.  Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. , 2006, Cancer cell.

[18]  C. Haglund,et al.  Cyclooxygenase-2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. , 2006, Oncology reports.

[19]  John T. Powers,et al.  Oncogenes and the DNA Damage Response: Myc and E2F1 Engage the ATM Signaling Pathway to Activate p53 and Induce Apoptosis , 2006, Cell cycle.

[20]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[21]  Xiaolong Wei,et al.  Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. , 2005, Cancer cell.

[22]  D. Desai,et al.  Effects of 3H-1,2-dithiole-3-thione, 1,4-phenylenebis(methylene)selenocyanate, and selenium-enriched yeast individually and in combination on benzo[a]pyrene-induced mutagenesis in oral tissue and esophagus in lacZ mice. , 2004, Mutation research.

[23]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[24]  S. Amin,et al.  Mammary carcinogenesis and molecular analysis of in vivo cII gene mutations in the mammary tissue of female transgenic rats treated with the environmental pollutant 6-nitrochrysene. , 2003, Carcinogenesis.

[25]  L. Magnelli,et al.  Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. , 2003, The American journal of pathology.

[26]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[27]  D Hoffmann,et al.  The Less Harmful Cigarette: a Controversial Issue. a Tribute to Ernst L. Wynder , 2000 .

[28]  K. Mancer,et al.  Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma , 2001, Oncogene.

[29]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[30]  R. Maronpot,et al.  High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors. , 1999, Cancer research.

[31]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[32]  T. Devereux,et al.  Predominant p53 G→A Transition Mutation and Enhanced Cell Proliferation in Uterine Sarcomas of CBA Mice Treated with 1,2-Dimethylhydrazine , 1998, Toxicologic pathology.

[33]  A. Olshan,et al.  p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[35]  A. Sarasin,et al.  Mutagenicity of a unique 8-oxoguanine in a human Ha-ras sequence in mammalian cells. , 1995, Carcinogenesis.

[36]  S. Amin,et al.  Synthesis of Fjord region diol epoxides as potential ultimate carcinogens of dibenzo[a,l]pyrene. , 1994, Chemical research in toxicology.

[37]  G. Snow,et al.  Risk of multiple primary tumors following oral squamous‐cell carcinoma , 1994, International journal of cancer.

[38]  T. Goodrow,et al.  Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. Blot,et al.  Second primary tumors in patients with oral cancer , 1992, Cancer.

[40]  D. Lane,et al.  Assessment of p53 protein expression in normal, benign, and malignant oral mucosa , 1992, The Journal of pathology.

[41]  A. Malliri,et al.  Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. , 1991, British Journal of Cancer.

[42]  S. Lippman,et al.  Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. , 1989, International journal of radiation oncology, biology, physics.

[43]  M. Spitz,et al.  Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. , 1989, International journal of radiation oncology, biology, physics.

[44]  Kramer Ir,et al.  Definition of leukoplakia and related lesions: an aid to studies on oral precancer. , 1978 .

[45]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[46]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[47]  Andreas Luch,et al.  On the impact of the molecule structure in chemical carcinogenesis. , 2009, EXS.

[48]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[49]  L. Kowalski,et al.  Presentation Risk factors for second cancers of the upper respiratory and digestive systems: A case-control study , 1991 .

[50]  L. Kowalski,et al.  Risk factors for second cancers of the upper respiratory and digestive systems: a case-control study. , 1991, Journal of clinical epidemiology.

[51]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[52]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  L. Sobin,et al.  Definition of leukoplakia and related lesions: an aid to studies on oral precancer. , 1978, Oral surgery, oral medicine, and oral pathology.